Use of adjuvant systemic therapy increasing for gastrointestinal stromal tumors (GIST)
the ONA take:
Localized gastrointestinal stromal tumors (GISTs) are rarely seen, but are the most common sarcomas in the gastrointestinal tract.
The approval of the drug imatinib and its use in adjuvant systemic treatment post-surgery for adult patients has changed GIST treatment in the last decade.
Researchers from the American Cancer Society wished to evaluate the evolving use of adjuvant therapy in GIST cases. They examined data from the National Cancer Data Base, reviewing the records of 4,694 patients diagnosed with GIST cases after 2004 to establish patterns of adjuvant therapy use.
The investigators discovered that between 2006 and 2007, the use of adjuvant systemic therapy in GIST cases more than doubled, only to drop in 2011. The peak point was in 2009, with nearly 38% of patients reviewed using adjuvant therapy.
Larger tumor size, an older patient age, or a non-minority white patient were all indicators of greater adjuvant systemic therapy use. The authors concluded that adjuvant systemic therapy use has increased by a significant margin in the last decade, acknowledging the modifying factors mentioned.
Results of this study were published online in the American Journal of Clinical Oncology.
Localized GISTs are rarely seen, but are the most common sarcomas in the gastrointestinal tract.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- High Symptom Burden With Polycythemia Vera Linked to QoL Impairment
- Bioimpedence Spectroscopy Improves Early Detection of Breast Cancer-Related Lymphedema in At-Risk Patients
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- MRD Negativity Associated With Prolonged Survival in Myeloma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Patient Navigation Reduces Delays in Diagnostic Resolution
- Fee-for-service Medicare Plans Linked to Improved Care During Last Year of Life
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|